Guided Therapeutics

Guided Therapeutics (GTHP) is a public, commercial-stage diagnostics company with a 30+ year mission to transform cancer screening through its non-invasive biophotonic platform. Its core achievement is the CE-marked LuViva system for cervical cancer detection, which provides immediate, point-of-care results and has demonstrated the potential for earlier detection than traditional methods in clinical studies. The company's strategy focuses on securing FDA approval, expanding international distribution via partners, and leveraging its platform technology into adjacent oncology diagnostics, such as esophageal cancer, to drive growth.

A patented biophotonic platform using multimodal hyperspectral imaging (reflectance and fluorescence spectroscopy) combined with AI algorithms to non-invasively detect physical and chemical changes in tissue indicative of pre-cancer and cancer.

GTI competes with large, entrenched players in cervical screening (e.g., Roche, Hologic) and the standard-of-care colposcopy procedure. Its differentiation lies in point-of-care immediacy, AI objectivity, and non-invasiveness, but overcoming clinical inertia and securing reimbursement are key challenges.